Autologous Bone Marrow Concentration for Rotator Cuff Tear

NCT ID: NCT03792594

Last Updated: 2020-04-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-05-12

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to evaluate the effect of bone marrow concentration on healing of rotator cuff tear by comparing clinical and imaging outcomes between patients receiving arthroscopic repair with intraoperative bone marrow concentration and those receiving arthroscopic repair only.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rotator cuff tear is a common cause of pain and disability among adults. Most tears are largely caused by the normal wear and tear that goes along with aging. Although nonsurgical treatment relieves pain and improves function in the shoulder, surgical repair for a torn rotator cuff is indicated if symptoms persisted or deteriorated after 3 months nonsurgical treatments, Recently, arthroscopic repair has become the mainstream of surgical repair for rotator cuff tear. However, the healing of a repaired tendon is not always predictable. Mesenchymal stem cells (MSCs) are pluripotent cells that can differentiate into multiple mesenchymal tissues, including tenocytes, chondrocytes and osteoblasts, as well as being a source of multiple growth factors to establish an environment conducive to soft and hard tissue regeneration. As bone marrow concentration has high concentration of mesenchymal stem cells, some studies have shown that autologous bone marrow concentration can improve the healing of tendon grafts in a bone tunnel. Therefore, the goal of this study was to evaluate the effect of bone marrow concentration on healing of rotator cuff.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rotator Cuff Tear Bone Marrow

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bone marrow concentration group

The patients receive arthroscopic repair with bone marrow concentration.

arthroscopic repair with bone marrow concentration

Intervention Type OTHER

arthroscopic repair with bone marrow concentration

Historical control group

The patients receive arthroscopic repair only

arthroscopic repair

Intervention Type OTHER

arthroscopic repair only

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

arthroscopic repair with bone marrow concentration

arthroscopic repair with bone marrow concentration

Intervention Type OTHER

arthroscopic repair

arthroscopic repair only

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* With diagnosis of rotator cuff tear
* Age between 40 and 70 years

Exclusion Criteria

* With prior history of shoulder surgery
* With current or prior history of trauma or infection at shoulder
* With current diagnosis of coagulopathy
* With current or prior history of cancer
* With current or prior history of hematological disease
* Pregnancy
* Patients who will not cooperate with one-year followup
Minimum Eligible Age

40 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aeon Biotechnology Corporation

INDUSTRY

Sponsor Role collaborator

Pei-Yuan Lee, MD

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pei-Yuan Lee, MD

Superintendent

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pei-Yuan Lee, MD

Role: STUDY_CHAIR

Show Chwan Memorial Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Show Chwan Memorial Hospital

Changhua, Changhua, Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chien-Sheng Lo, MD

Role: CONTACT

+886-975611289

Pei-Yuan Lee, MD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Chien-Sheng Lo, MD

Role: primary

+886-975611289

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RD106055

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.